The long term goal of our laboratory is to identify novel therapeutic targets for triple-negative breast cancer (TNBC), which lacks estrogen receptor, progesterone receptor, and HER2. To reach this goal, we are studying: 1) molecular determinants of TNBC therapy resistance, and 2) contributions of adipose stem cells to TNBC initiation/ progression.
Education and Training
- Instructor in Medicine, Medicine, Harvard University , 1997 - 2005
- Research Fellow, Pediatric Oncology, Harvard University , 1996 - 1997
- Research Fellow, Medicine, Harvard University , 1995 - 1996
- Ph.D., Harvard University , 1995